SCHEMBL4167713

SCHEMBL4167713

Cc1ccc2c(c1)C1(NC(=O)NC1=O)C(=O)N2CCn1cccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 3/20 0.40
ITGA4 P13612 1/20 0.34
ALDH1A1 P00352 5/20 0.34
MAPT P10636 3/20 0.34
POLB P06746 2/20 0.33
ADAMTS5 Q9UNA0 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PKM P14618 1/20 0.33
CNR1 P21554 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
CACNA1F O60840 1/20 0.33
CYP2C9 P11712 1/20 0.33
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
SCN1A P35498 1/20 0.33
SCN4A P35499 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
CACNA1D Q01668 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4169748 0.86 AKR1B1 (0.48) AKR1B1ALDH1A1MAPTLMNAMEN1
SCHEMBL4169609 0.86 AKR1B1 (0.48) AKR1B1
SCHEMBL4169851 0.84 ITGA4 (0.44) AKR1B1ITGA4ALDH1A1MAPTSMN1; SMN2
SCHEMBL4169551 0.83 ALDH1A1 (0.51) AKR1B1ALDH1A1MAPTADAMTS5SMN1; SMN2
SCHEMBL4255427 0.82 MAPT (0.45) AKR1B1ALDH1A1MAPTSMN1; SMN2CNR1
SCHEMBL4254388 0.82 AKR1B1 (0.41) AKR1B1ALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4164829 0.82 AKR1B1 (0.41) AKR1B1ALDH1A1MAPTPOLBADAMTS5
SCHEMBL4170928 0.81 AKR1B1 (0.39) AKR1B1ALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4171124 0.81 AKR1B1 (0.39) AKR1B1ALDH1A1MAPTPOLBSMN1; SMN2
SCHEMBL4170549 0.80 ALDH1A1 (0.52) ALDH1A1MAPTPOLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US claimed
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 AKR1B1 344/4885ITGA4 1856/4885ALDH1A1 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.